by those agreements or decisions, and to indicate the estimated production volume covered and the expected time period of implementation. another obligation is to communicate, no later than days after the six-month period, the actual production volume. the member states, in turn, are required, in accordance...
interests of the patient. in addition, the united states alleged that trans promoted the sale and use of its axialif system for uses that were not approved or cleared by the u.s. food and drug administration, including use in certain procedures to treat complex spine deformity, and which were thus not covered...
conduct identified in the settlement agreement, but without prejudice as to the united states as to any conduct that falls outside the scope of the covered conduct. acting united states attorney walt green stated, "our office has made fighting health care fraud a top priority in this district, through...